Movement Alert｜DUALITYBIO-B Falls 5.23% in Regular Trading, GSK Competitive Pressure and Lock-up Expiry Concerns Persist

Market Focus08-03

On August 3, DUALITYBIO-B fell 5.23% in regular trading, trading at 171.8 HKD/share with turnover of approximately 28.44 million HKD. The stock continues its downward trajectory following a 13.7% plunge on July 30.

The primary catalyst remains GSK's half-year report, which dramatically elevated the strategic priority of its B7-H3 ADC pipeline Ris-Rez, designating it as the core growth engine for its oncology business beyond 2031. GSK plans approximately 6 new Phase III trials for Ris-Rez alone, covering SCLC, NSCLC, prostate cancer, and colorectal cancer. This directly challenges DUALITYBIO-B's core pipeline DB-1311/BNT324, also a B7-H3 ADC co-developed with BioNTech, as both pursue nearly identical combination therapy strategies pairing B7-H3 ADC with PD-(L)1/VEGF bispecifics.

Additionally, market concerns persist regarding potential selling pressure from cornerstone investors following lock-up expiry, compounded by the company's substantial R&D capital requirements after exercising its US co-development and co-commercialization option.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168818191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168818191","market":"us","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Falls 5.23% in Regular Trading, GSK Competitive Pressure and Lock-up Expiry Concerns Persist","media":"Market Focus","content":"<p><p>On August 3, DUALITYBIO-B fell 5.23% in regular trading, trading at 171.8 HKD/share with turnover of approximately 28.44 million HKD. The stock continues its downward trajectory following a 13.7% plunge on July 30.</p><p>The primary catalyst remains GSK's half-year report, which dramatically elevated the strategic priority of its B7-H3 ADC pipeline Ris-Rez, designating it as the core growth engine for its oncology business beyond 2031. GSK plans approximately 6 new Phase III trials for Ris-Rez alone, covering SCLC, NSCLC, prostate cancer, and colorectal cancer. This directly challenges DUALITYBIO-B's core pipeline DB-1311/BNT324, also a B7-H3 ADC co-developed with BioNTech, as both pursue nearly identical combination therapy strategies pairing B7-H3 ADC with PD-(L)1/VEGF bispecifics.</p><p>Additionally, market concerns persist regarding potential selling pressure from cornerstone investors following lock-up expiry, compounded by the company's substantial R&D capital requirements after exercising its US co-development and co-commercialization option.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Falls 5.23% in Regular Trading, GSK Competitive Pressure and Lock-up Expiry Concerns Persist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Falls 5.23% in Regular Trading, GSK Competitive Pressure and Lock-up Expiry Concerns Persist\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 09:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, DUALITYBIO-B fell 5.23% in regular trading, trading at 171.8 HKD/share with turnover of approximately 28.44 million HKD. The stock continues its downward trajectory following a 13.7% plunge on July 30.</p><p>The primary catalyst remains GSK's half-year report, which dramatically elevated the strategic priority of its B7-H3 ADC pipeline Ris-Rez, designating it as the core growth engine for its oncology business beyond 2031. GSK plans approximately 6 new Phase III trials for Ris-Rez alone, covering SCLC, NSCLC, prostate cancer, and colorectal cancer. This directly challenges DUALITYBIO-B's core pipeline DB-1311/BNT324, also a B7-H3 ADC co-developed with BioNTech, as both pursue nearly identical combination therapy strategies pairing B7-H3 ADC with PD-(L)1/VEGF bispecifics.</p><p>Additionally, market concerns persist regarding potential selling pressure from cornerstone investors following lock-up expiry, compounded by the company's substantial R&D capital requirements after exercising its US co-development and co-commercialization option.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1168818191","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168818191","pubTimestamp":1785721553,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, DUALITYBIO-B fell 5.23% in regular trading, trading at 171.8 HKD/share with turnover of approximately 28.44 million HKD. The stock continues its downward trajectory following a 13.7%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势警报|DUALITYBIO-B 常规交易下跌 5.23%，葛兰素史克竞争压力和锁定到期担忧持续存在","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On August 3, DUALITYBIO-B fell 5.23% in regular trading, trading at 171.8 HKD/share with turnover of approximately 28.44 million HKD. The stock continues its downward trajectory following a 13.7% plunge on July 30.The primary catalyst remains GSK's half-year report, which dramatically elevated the strategic priority of its B7-H3 ADC pipeline Ris-Rez, designating it as the core growth engine for its oncology business beyond 2031. GSK plans approximately 6 new Phase III trials for Ris-Rez alone, covering SCLC, NSCLC, prostate cancer, and colorectal cancer. This directly challenges DUALITYBIO-B's core pipeline DB-1311/BNT324, also a B7-H3 ADC co-developed with BioNTech, as both pursue nearly identical combination therapy strategies pairing B7-H3 ADC with PD-(L)1/VEGF bispecifics.Additionally, market concerns persist regarding potential selling pressure from cornerstone investors following lock-up expiry, compounded by the company's substantial R&D capital requirements after exercising its US co-development and co-commercialization option.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168818191","isCrawlerRequest":true}